No evidence for a protective effect of naturally induced HPV antibodies on subsequent anogenital HPV infection in HIV-negative and HIV-infected MSM

Mooij, Sofie H.; Landén, Olivia; Klis, Fiona R.M. van der; Sande, Marianne A. B. van der; Melker, Hester E. de; Coutinho, Roel A.; Eeden, Arne van; Rooijen, Martijn S. van; Meijer, Chris J.L.M.; Loeff, Maarten F. Schim van der

doi:10.1016/j.jinf.2014.06.003

Cited by 18 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 While we did not find evidence that HPV16 L1 seropositivity protects against subsequent oral HPV16 infection, it is unclear whether it may have a differential impact on infection risk at different anatomical sites. Several studies have suggested that HPV16 L1 seropositivity may partially protect against subsequent cervical HPV infection; 4–6 but it is unclear if that protection is conferred against HPV at other anatomical sites as two other recent studies observed no protection for penile 22,23 or anal HPV acquisition in men. 23 However, there are several caveats to our finding that HPV16 L1 seropositivity may not impact risk of oral HPV16 infection that need to be considered as the results may differ by population, HPV type, titer level, or by assay.…”

Section: Discussionmentioning

confidence: 99%

A Longitudinal Study of Human Papillomavirus 16 L1, E6, and E7 Seropositivity and Oral Human Papillomavirus 16 Infection

Beachler

Viscidi

Sugar

et al. 2015

Sexually Transmitted Diseases

View full text Add to dashboard Cite

Background Individuals with HPV infections can develop IgG antibodies to HPV proteins including the L1 capsid and E6 and E7 oncoproteins. Evidence on whether L1 antibodies reduce the risk of cervical HPV infection is mixed, but this has not been explored for oral HPV infections. Antibodies to HPV16’s E6 oncoprotein have been detected in some oropharyngeal cancer cases years prior to cancer diagnosis, but it is unknown if these antibodies are associated with oral HPV16 DNA. Methods Enzyme linked immunosorbent assays tested for serum antibodies to HPV16’s L1 capsid in 463 HIV-infected and 293 HIV-uninfected adults, and for antibodies to recombinantly expressed E6 and E7 oncoproteins to HPV16 in 195 HIV-infected and 69 HIV-uninfected cancer-free participants at baseline. Oral rinse samples were collected semi-annually for up to three years and tested for HPV DNA using PGMY 09/11 primers. Adjusted Poisson, logistic, and Wei-Lin-Weissfeld regression models were utilized. Results HPV16 L1 seroreactivity did not reduce the subsequent risk of incident oral HPV16 infection in unadjusted (HR=1.4, 95%CI=0.59–3.3) or adjusted (aHR=1.1, 95%CI=0.41–3.0) analysis. Antibodies to HPV16 E6 and E7 oncoproteins were detected in 7.6% and 3.4% of participants respectively, but they were not associated with baseline oral HPV16 DNA prevalence or oral HPV16 persistence (each p-value>0.40). Conclusions Naturally acquired HPV16 L1 antibodies did not reduce the risk of subsequent oral HPV16 infection. HPV16 E6 and E7 seropositivity was not a marker for oral HPV16 infection in this population without HPV-related cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

A Longitudinal Study of Human Papillomavirus 16 L1, E6, and E7 Seropositivity and Oral Human Papillomavirus 16 Infection

Beachler

Viscidi

Sugar

et al. 2015

Sexually Transmitted Diseases

View full text Add to dashboard Cite

show abstract

“…Nevertheless, seroprevalence was high in our study population. Some studies have suggested that antibodies induced by natural infection may not be protective against subsequent HPV [35, 36]; if men with detectable antibody who cleared a previous natural infection are not protected from repeat infections with that type, we might be underestimating the percentage of MSM standing to benefit from vaccination.…”

Section: Discussionmentioning

confidence: 99%

Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men—United States, 2012–2014

et al. 2016

View full text Add to dashboard Cite

Background Gay, bisexual, and other men who have sex with men (MSM) are at high risk for human papillomavirus (HPV) infection; vaccination is recommended for US males, including MSM through age 26 years. We assessed evidence of HPV among vaccine-eligible MSM and transgender women to monitor vaccine impact. Methods During 2012–2014, MSM aged 18–26 years at select clinics completed a computer-assisted self-interview regarding sexual behavior, human immunodeficiency virus (HIV) status, and vaccinations. Self-collected anal swab and oral rinse specimens were tested for HPV DNA (37 types) by L1 consensus polymerase chain reaction; serum was tested for HPV antibodies (4 types) by a multiplexed virus-like particle–based immunoglobulin G direct enzyme-linked immunosorbent assay. Results Among 922 vaccine-eligible participants, the mean age was 23 years, and the mean number of lifetime sex partners was 37. Among 834 without HIV infection, any anal HPV was detected in 69.4% and any oral HPV in 8.4%, yet only 8.5% had evidence of exposure to all quadrivalent vaccine types. In multivariate analysis, HPV prevalence varied significantly (P < .05) by HIV status, sexual orientation, and lifetime number of sex partners, but not by race/ethnicity. Discussions Most young MSM lacked evidence of current or past infection with all vaccine-type HPV types, suggesting that they could benefit from vaccination. The impact of vaccination among MSM may be assessed by monitoring HPV prevalence, including in self-collected specimens.

show abstract

“…In the few studies that have assessed the association of antibodies generated following natural HPV infection and protection against subsequent genital HPV infections in men, results have either been inconclusive or have not shown an association (14, 15, 16). The current study is an extended analysis of previous work from our group (14), in which we showed a non-significant increased risk for incident (aHR 1.22, 95% CI 0.83, 1.79) and persistent HPV 16 genital infections (aHR 1.05, 95% CI 0.51, 2.16).…”

Section: Discussionmentioning

confidence: 99%

“…Due to the differences in HPV seroprevalence by sexual orientation, stratified analyses were also conducted. To evaluate whether antibody levels were associated with subsequent detection of incident infections, we categorized serum antibody levels into the highest tertile and lowest two tertiles and compared these two groups to seronegative men (9, 16). …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study

et al. 2016

View full text Add to dashboard Cite

Naturally induced serum antibodies against HPV may affect risks of subsequent incident genital infections by HPV 6, 11, 16, or 18 in men. In this study, we examined the hypothesis by following 4,123 healthy men every six months(median follow-up time 4.1 years). HPV antibodies were measured at baseline using a virus-like particle-based ELISA assay. Genital HPV genotypes were detected using Roche Linear Array. Incidence proportions and six-month persistence proportions were calculated at six-month intervals. Kaplan-Meier curves and Cox models were used to assess genotype-specific cumulative incidence and hazard ratios (HR), respectively. HPV 6, 11, 16, and 18 seroprevalence was 8.1%, 13.9%, 12.7%, and 10.8%, respectively. Significantly higher rates of incident infections were observed for HPV 16 among baseline seropositive men (adjusted HR 1.37, 95% CI 1.01–1.86), with similar but non-significant HRs for six-month persistent infections. Risk of persistent HPV 18 infection was significantly lower among seropositive men in the unadjusted model (HR 0.22, 95% CI 0.06–0.91), but not in the adjusted model (HR 0.19, 95% CI 0.03–1.37). Incident and six-month persistent infections for HPV 6 and 11 did not differ by baseline serostatus. Baseline serostatus among men was not associated with a reduction in subsequent incident genital HPV 6, 11, and 16 infections. However, protection against persistent HPV 18 infections was observed in unadjusted models. Our research suggests a need of further studies to examine the potentially protective effects of naturally induced HPV18 antibodies in men.

show abstract

No evidence for a protective effect of naturally induced HPV antibodies on subsequent anogenital HPV infection in HIV-negative and HIV-infected MSM

Cited by 18 publications

References 33 publications

A Longitudinal Study of Human Papillomavirus 16 L1, E6, and E7 Seropositivity and Oral Human Papillomavirus 16 Infection

A Longitudinal Study of Human Papillomavirus 16 L1, E6, and E7 Seropositivity and Oral Human Papillomavirus 16 Infection

Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men—United States, 2012–2014

Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study

Contact Info

Product

Resources

About